glp-1 obesity drug market size 2025 The United States Agonists Weight Loss Drugs & Outlook, 2030 GLP-1 Agonists Market Report 2025-2033,

[DOI] [PubMed] [Google Scholar] 57.Witkowski M., Moreno S.I., Fernandes J., Johansen P., Augusto M., Nair S

10.1007/s12325-009-0014-9 182 TanX.HuJ

Its one of the oldest weight loss medications available, usually prescribed short-term (typically up to 12 weeks)

Retatrutide and placebo demonstrated a clear difference in fat content, establishing that the drugs primary activity is on fat, not muscle

PI3K is activated by the GLP-1 receptor coupled G subunits which consequently activate mitogen-activated protein kinases (MAPK), initiating gene expression that controls cell growth, repair, and differentiation [33, 37]